46% power in study planning? [Study As­sess­ment]

posted by Helmut Homepage – Vienna, Austria, 2013-08-01 15:18 (4301 d 19:42 ago) – Posting: # 11147
Views: 26,056

Hi Sam,

❝ In my study there were five subjects whose data for the test products are not in concurrence to the other subjects data.


Can you please be more specific. What do you mean by “not in concurrence to the other subjects data”?

❝ Should I remove the AUCt parameter only for that subjects which have AUCextrap value more than 20%…


No. You should evaluate the study based on the statistical analysis plan / clinical study protocol. Everything else (post hoc exclusion) is cherry-picking and not acceptable. You can exclude this subjects only in an additional evaluation and present it as a sensitivity analysis.

❝ … write a comment on the report as per our suggestions.


I would try that (i.e., AUCt is not a reliable/relevant metric of absorption for ER formulations). Back it up with a comparison of half lives.

❝ Since the ratio in the pilot study was around 84% and considering the ISCV of around 26%. The actual sample size come to be around 138.


Can you elaborate? With T/R of 84% and a CV of 26% you would have needed 342 (!) subjects to obtain 80% power (and still 260 for 70% power – which is the lowest any serious IEC should accept, IMHO). Was your target power only 46% – knowingly running another “casino-type” study? Bad.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
130 visitors (0 registered, 130 guests [including 4 identified bots]).
Forum time: 11:01 CEST (Europe/Vienna)

If you shut your door to all errors
truth will be shut out.    Rabindranath Tagore

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5